Notify me when Fairmount Funds Management LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 13 | $1,313,784,318 | +$67,452,086 | -$320,282,824 | -$252,830,738 | COGT, APGE, SYRE, VRDN, ORKA | 13F-HR | 17 Feb 2026, 15:45 |
| Q3 2025 | 17 | $1,111,423,463 | +$130,479,553 | -$8,845,241 | +$121,634,312 | DNTH, COGT, AXSM, APGE, ELVN | 13F-HR | 14 Nov 2025, 15:45 |
| Q2 2025 | 17 | $771,902,136 | +$108,432,779 | -$10,217,735 | +$98,215,044 | APGE, AXSM, ELVN, SRRK, SYRE | 13F-HR | 14 Aug 2025, 15:45 |
| Q1 2025 | 15 | $644,620,652 | $0 | -$231,178,384 | -$231,178,384 | AXSM, APGE, SYRE, ELVN, NUVL | 13F-HR | 15 May 2025, 15:45 |
| Q4 2024 | 17 | $1,005,884,370 | +$131,897,489 | -$127,095,451 | +$4,802,038 | AXSM, NUVL, SYRE, APGE, SRRK | 13F-HR | 14 Feb 2025, 15:45 |
| Q3 2024 | 15 | $1,233,275,095 | +$223,089,301 | -$84,795,111 | +$138,294,190 | AXSM, NUVL, APGE, SYRE, ELVN | 13F-HR | 14 Nov 2024, 15:45 |
| Q2 2024 | 13 | $885,124,128 | +$179,688,846 | -$149,171,796 | +$30,517,050 | AXSM, NUVL, SYRE, APGE, ELVN | 13F-HR | 14 Aug 2024, 15:45 |
| Q1 2024 | 15 | $917,385,636 | +$115,359,680 | -$355,532,049 | -$240,172,369 | AXSM, NUVL, APGE, DNTH, KNSA | 13F-HR | 15 May 2024, 15:45 |
| Q4 2023 | 16 | $946,456,168 | +$33,945,726 | -$153,793,843 | -$119,848,117 | AXSM, IMGN, NUVL, APGE, RYZB | 13F-HR | 14 Feb 2024, 15:46 |
| Q3 2023 | 20 | $831,172,751 | +$228,549,240 | -$48,543,788 | +$180,005,452 | AXSM, NUVL, IMGN, APGE, MRUS | 13F-HR | 14 Nov 2023, 15:45 |
| Q2 2023 | 17 | $709,301,537 | +$208,331,119 | -$142,840,131 | +$65,490,988 | AXSM, NUVL, IMGN, ELVN, COGT | 13F-HR | 14 Aug 2023, 15:36 |
| Q1 2023 | 16 | $581,468,614 | +$88,579,455 | -$82,942,311 | +$5,637,144 | AXSM, NUVL, VRNA, BGNE, ELVN | 13F-HR | 15 May 2023, 09:09 |
| Q4 2022 | 16 | $630,363,234 | +$86,101,660 | -$146,016,800 | -$59,915,140 | AXSM, NUVL, VRNA, BGNE, VRDN | 13F-HR | 14 Feb 2023, 15:31 |
| Q3 2022 | 26 | $542,122,000 | +$109,415,559 | -$70,276,349 | +$39,139,210 | AXSM, COGT, NUVL, BCRX, BHVN | 13F-HR | 09 Nov 2022, 09:59 |
| Q2 2022 | 27 | $436,929,000 | +$140,146,165 | -$64,231,303 | +$75,914,862 | BHVN, AXSM, BCRX, GBT, ARGX | 13F-HR | 15 Aug 2022, 17:23 |
| Q1 2022 | 22 | $422,935,000 | +$179,192,542 | -$40,662,000 | +$138,530,542 | INSM, GBT, ARGX, AXSM, ENTA | 13F-HR | 16 May 2022, 16:00 |
| Q4 2021 | 20 | $303,335,000 | +$56,277,724 | -$15,872,517 | +$40,405,207 | ZGNX, INSM, ENTA, ARGX, GBT | 13F-HR | 14 Feb 2022, 16:30 |
| Q3 2021 | 20 | $274,991,000 | +$77,673,199 | -$37,082,380 | +$40,590,819 | INSM, ZGNX, NUVL, ALLK, ENTA | 13F-HR | 15 Nov 2021, 16:23 |
| Q2 2021 | 19 | $243,235,000 | +$56,277,556 | -$24,792,452 | +$31,485,104 | INSM, ZGNX, AXSM, ARGX, IOVA | 13F-HR | 13 Aug 2021, 11:24 |
| Q1 2021 | 21 | $237,245,000 | +$37,138,962 | -$20,520,227 | +$16,618,735 | INSM, ZGNX, IOVA, ALLK, AXSM | 13F-HR | 14 May 2021, 09:28 |
| Q4 2020 | 18 | $279,600,000 | +$39,270,727 | -$45,418,244 | -$6,147,517 | INSM, FOLD, IOVA, ACAD, TRILLIUM THERAPEUTICS INC | 13F-HR | 12 Feb 2021, 10:45 |
| Q3 2020 | 17 | $236,102,000 | +$28,441,162 | -$7,329,042 | +$21,112,120 | INSM, ACAD, TRILLIUM THERAPEUTICS INC, FOLD, IOVA | 13F-HR | 12 Nov 2020, 15:42 |
| Q2 2020 | 14 | $224,208,000 | +$13,139,456 | -$10,420,409 | +$2,719,047 | ACAD, INSM, ZGNX, FOLD, AXSM | 13F-HR | 04 Aug 2020, 16:02 |
| Q1 2020 | 14 | $164,882,000 | +$55,094,066 | -$10,232,604 | +$44,861,462 | ACAD, ZGNX, INSM, IOVA, FOLD | 13F-HR | 08 May 2020, 10:20 |
| Q4 2019 | 15 | $164,989,000 | $0 | $0 | $0 | ZGNX, INSM, ACAD, AMRN, IOVA | 13F-HR | 12 Feb 2020, 16:05 |